RT Journal Article
SR Electronic
T1 Prevalence of diabetic macular edema and risk factors among diabetic patients at the University of Gondar Tertiary Eye Care and Training Center, North West Ethiopia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.13.22273816
DO 10.1101/2022.04.13.22273816
A1 Kabtu, Endale
A1 Tsegaw, Asamere
YR 2022
UL http://medrxiv.org/content/early/2022/04/17/2022.04.13.22273816.abstract
AB BACKGROUND Diabetic macular edema (DME) is the most common cause of visual impairment in patients with diabetes mellitus. The prevalence of DME globally is around 6.8 % and in Ethiopia range from 5.7% to 11%.Different factors are associated with DME including poor glycemic control, longer duration, hypertension, dyslipidemiaOBJECTIVE To determine the prevalence and associated factors of diabetic macular edema among diabetic patients attending University of Gondar (UOG) hospital, tertiary eye care and training center, NW EthiopiaMETHODS A hospital based cross-sectional study was conducted from March 2021 to October 2021. Socio-demographic, clinical and laboratory data of patients was gathered. The collected data was entered into epi-data 4.6 version, exported to SPSS version 20 and analyzed.RESULTS A total of 165 diabetic patients were enrolled with mean age of 54.71 ±13.66 years, 50.9% male, 85.5% urban dwellers, 79.9% type 2 DM, 49.7% on oral hypoglycemic agents and the mean duration of diabetes was 7.93 years. Cataract was the commonest ocular morbidity and 42% of patients had at least mild vision impairment. The overall prevalence of DME was 17% and 5.5% of patients had clinically significant macular edema (CSME). The presence of proteinuria was 8.04 times more likely to have DME.CONCLUSION The prevalence of DME among our patients was high. The presence of proteinuria was significantly associated with DME. Screening of diabetic patients for sight threatening retinopathy early and appropriate treatment is recommended.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAClinical Protocols NA Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted after ethical clearance was obtained from University of Gondar ethical review board (ID=UOG/ER/130/2022). Informed written consent was obtained from the study participants after clear explanation concerning the purpose and importance of the study. The identity of the patient was not exposed in any way and confidentiality of patient record was respected.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files. NA